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Abstract
Background: The elevation of plasma homocysteine (Hcy) and C-reactive protein (CRP) has been correlated to an increased
risk of Parkinson’s disease (PD) or vascular diseases. The association and clinical relevance of a combined assessment of Hcy
and CRP levels in patients with PD and vascular parkinsonism (VP) are unknown.
Methodology/Principal Findings: We performed a cross-sectional study of 88 Chinese patients with PD and VP using a
clinical interview and the measurement of plasma Hcy and CRP to determine if Hcy and CRP levels in patients may predict
the outcomes of the motor status, non-motor symptoms (NMS), disease severity, and cognitive declines. Each patient’s NMS,
cognitive deficit, disease severity, and motor status were assessed by the Nonmotor Symptoms Scale (NMSS), Mini-Mental
State Examination (MMSE), the modified Hoehn and Yahr staging scale (H&Y), and the unified Parkinson’s disease rating
scale part III (UPDRS III), respectively. We found that 100% of patients with PD and VP presented with NMS. The UPDRS III
significantly correlated with CRP (P=0.011) and NMSS (P=0.042) in PD patients. The H&Y was also correlated with Hcy
(P=0.002), CRP (P=0.000), and NMSS (P=0.023) in PD patients. In VP patients, the UPDRS III and H&Y were not significantly
associated with NMSS, Hcy, CRP, or MMSE. Strong correlations were observed between Hcy and NMSS as well as between
CRP and NMSS in PD and VP.
Conclusions/Significance: Our findings support the hypothesis that Hcy and CRP play important roles in the pathogenesis
of PD. The combination of Hcy and CRP may be used to assess the progression of PD and VP. Whether or not anti-
inflammatory medication could be used in the management of PD and VP will produce an interesting topic for further
research.
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Introduction
Idiopathic Parkinson’s disease (PD) is the second most common
neurodegenerative disorder following Alzheimer’s disease; howev-
er, attention has recently been drawn to vascular parkinsonism
(VP). Inflammatory mechanisms have been recognized to play
important roles in the pathogenesis and development of PD and
VP, and various inflammatory biomarkers have been investigated
as potential predictors of PD and VP. Several lines of research
have shown that serum oxidative stress and pro-inflammatory
cytokines such as interleukin (IL)-1b, IL-2, IL-6, HLA-DRB1,
phospholipase A(2), tumor necrosis factor (TNF)-a, and TNF-a
receptors are elevated in the brain and cerebral spinal fluid of PD
patients [1,2,3,4].
In addition to those inflammatory related mediators, plasma C-
reactive protein (CRP) and homocysteine (Hcy) levels have recently
attracted wide clinical attention as predictive of PD progression.
One clinical study by Song indicated that CRP levels in an early PD
group werehigherthanthoseofhealthycontrols[5].A similarresult
has been observed in another study, which demonstrated an
elevated serum CRP in PD and ischemic cerebrovascular disease
compared to control subjects [6]. It has been documented that the
plasma concentration of Hcy is elevated in PD patients, and this
increase is associated with the long-term effects of chronic or acute
administration of L-dopa [7,8,9,10]. Investigations on the associa-
tion of Hcy with PD dementia (PDD) have shown conflicting results
[11]; some studies didnot observe a directrelationship between Hcy
plasma levels and cognitive impairment and dementia in PD [7,12],
while others found a significant correlation of hyperhomocysteine-
mia with the presence of dementia in PD [8,13]. However, to the
best of our knowledge, few studies have been performed to
investigate the combined effects of Hcy and CRP in PD and VP.
PD patients are characterized by typical motor symptoms (MS),
such as bradykinesia, resting tremor, and rigidity, as well as non-
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Patients normally show an increasing severity of NMS as the
disease develops, although some of the NMS, such as depression
and impaired cognition, may occur in the premotor stage of this
disease [15]. Whether the severity and progression of PD and VP,
as measured by MS and NMS, could be evaluated by the
combination of Hcy and CRP is an interesting topic. We
undertook this study to determine whether plasma Hcy and
CRP levels in patients with PD and VP are associated with the
development of the diseases and their cognitive dysfunctions. The
primary aim of this study was to use different clinical parameters to
compare PD and VP and to describe the correlation between the
symptom scores and plasma Hcy and CRP levels in patients with
PD and VP. An additional aim was to assess whether Hcy and
CRP in PD and VP are associated with poor motor function and
L-dopa dosage. A third aim of this study was to conduct an
exploratory analysis to identify the association of NMSS domains
and plasma Hcy/CRP levels.
Methods
Patients
This cross-sectional study was carried out at the Department of
Neurology of the Third Affiliated Hospital of Sun Yat-sen
University, Guangzhou, P. R. China. From July 2009 to
December 2010, 43 patients (25 males and 18 females) with PD
and a mean age (6 SD) of 58.9613.7 (Table 1) were recruited
from the inpatient/outpatient clinic. The patients were identified
according to the United Kingdom PD Society Brain Bank
(UK-PDSBB) criteria for the diagnosis of idiopathic PD [16]. In
addition, 45 patients (23 males and 22 females) with VP and a
mean age (6 SD) of 67.0611.6 (Table 1) were recruited according
to the Zijlmans’ criteria for the diagnosis of VP [17].
Ethics Statement
The local Ethics Committee of Third Affiliated Hospital of Sun
Yat-sen University approved the study, which has been conducted
according to the principles expressed in the Declaration of
Helsinkiand. The patients gave informed consent for the
investigation. This consent was verbal for those measurements
on MMSE,H&Y,UPDRS(III), and NMSS in this study. All those
measurements were anonymously in this study. Since those
measurements benefit to the therapies of PD and VP patients
involved in this study, the ethics committee specifically approved
that procedure and wish those measurements become a routine
way for the treatment of PD and VP patients in the future. The
consent for the measurement of plasma homocysteine and C-
reactive protein was written.
Study Design
Experienced neurologists performed the evaluations and
completed neurological examinations of the inpatients and
outpatients. All patients with PD in this study fulfilled the criteria
of the UK-PDSBB [16]. The exclusion criteria were as follows: (1)
PD patients with disability due to neurological disorders other
than PD, such as cerebrovascular disease, sequelae, or psychosis
[18]; (2) PD patients with somatic diseases that could have a
potential effect on NMS (e.g., pain syndromes, advanced diabetes
mellitus, malignancy, renal, hepatic or heart failure, severe
anemia, or any other acute or chronic debilitating or life-
threatening disease/state) [18]; (3) PD patients with moderate/
severe cognitive impairment, as determined by a Mini-Mental
Table 1. Demographic, motor, and non-motor parameters.
Clinical parameters PD VP
Mean(SD) Min Max Mean(SD) Min Max
Gender (n) Male n(%) 25(58.1) 23(51.1)
Female n(%) 18(41.9) 22(49.9)
Age (years) 58.9(13.74) 40 83 67.0 (11.6) 45 83
Disease duration (years) 6.2(3.7) 0.08 26 5.8(4.2) 0.06 14
H&Y 2.39(1.09) 1 6 2.34(1.28) 1 4
Daily L-dopa dosage (mg) 392.3(225.3) 200 800 383.3(189.9) 200 800
BMI 22.80(2.12) 19.22 25.39 21.68(2.37) 18.32 25.39
MMSE 25.32(2.18) 21 30 22.08(2.93) 18 30
UPDRS(III) 17.89(5.65) 6 29 19.23(10.60) 8 33
NMSS(total) 131.14(9.24) 47 219 135.57(48.76) 41 235
Cardiovascular 2.21(3.87) 0 9 2.64(2.31) 0 8
Sleep/Fatigue 28.14(3.92) 0 46 26.57(10.11) 0 46
Mood 27.14(13.31) 0 58 26.43(12.38) 0 55
Perceptual problem 7.36(3.42) 0 22 9.71(7.67) 0 26
Attention/memory 13.29(6.60) 0 22 13.07(7.42) 0 21
Gastrointestina 11.57(9.15) 0 32 12.57(8.78) 0 31
Urinary 13.21(9.93) 0 32 12.36(8.10) 0 36
Sexual function 13.64(5.0) 0 24 15.86(6.8) 0 24
Miscellaneous 15.64(10.72) 0 36 16.36(9.79) 0 38
Abbreviations: SD, Standard deviation; BMI, Body Mass Index; MMSE, mini-mental state examination; UPDRS III, the unified Parkinson’s disease rating scale part III; H&Y,
the modified Hoehn and Yahr staging scale; and NMSS, non-motor symptoms scale for Parkinson’s disease (range of possible scores from 0 to 360).
doi:10.1371/journal.pone.0019333.t001
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score lower than the median value determined in a reference
population-based sample of corresponding age and education
[15,19]; and (4) individuals who refused to participate in the study.
All patients with VP in this study fulfilled the criteria according to
Benamer and Zijlmans’ reports [17,20] as follows: (1) parkinsonism,
defined as bradykinesia, and at least one of the following: rest
tremor, rigidity or postural instability; (2) cerebrovascular disease,
defined as evidence of relevant cerebrovascular disease by brain
imaging or the presence of focal signs or symptoms that are
consistent with stroke; and (3) a relationship between (1) and (2): an
acute or delayed progressive onset of parkinsonism (within 1 year)
after stroke with evidence of infarcts in or near areas that increase
the basal ganglion motor output or decrease the thalamocortical
drive directly, or an insidious onset of parkinsonism with extensive
sub-cortical white matter lesions, bilateral symptoms at the onset
and the presence of early shuffling gait or early cognitive
dysfunction.Allsubjectscompletedthefollowingbatteryofstandard
assessment measures: a standard demography form, the unified
Parkinson’s disease rating scale part III (UPDRS III- motor) [21]
and the modified Hoehn and Yahr staging scale (H&Y) [22]. The
UPDRS III-motor and H&Y scales were used to evaluate motor
dysfunctions and disease severity. The degree of NMS in every
patient was measured by the NMSS [23]. Cognitive abilities were
evaluated with the MMSE [19]. All scales were available and
validated for the Chinese population. The demographics and
clinical data of the subjects are shown in Table 1.
Venous blood samples for CRP and Hcy measurement were
obtained from all subjects in the study. The serum was separated
within the hour by centrifugation at 3,000 rpm for 10 min, and
the separated sera were stored at 270uC until the laboratory
evaluation.The CRP level was measured by latex immunoturbidi-
metric assay according to Ichihara’s study [24], and the plasma
level of Hcy was determined using a solid phase competitive
chemiluminescent enzyme immunoassay [7].
Statistical analysis
All data for the continuous variables (age, disease duration, daily
levodopa dosage, UPDRS III, MMSE, NMSS, Hcy, and CRP) are
shown as the means 6 standard deviation, and the categorical
variable (gender) is shown as a percentage.The total scores of
UPDRS III, MMSE, NMSS, Hcy, and CRP were calculated by
summing single items. The strength of the association for
correlation coefficients was interpreted as follows: #0.19,
negligible; 0.20 to 0.39, weak; 0.40 to 0.59, moderate; 0.60 to
0.79, strong; and $0.80, very strong [25]. Student’s t-test was used
to compare the differences of age, Hcy, CRP, BMI, MMSE,
UPDRS III, and NMSS between PD and VP patients. A
Spearman’s rank correlation coefficient was used to evaluate the
association among UPDRS III and Hcy/CRP, UPDRS III and
MMSE/NMSS, nine different NMSS domains and Hcy/CRP,
Hcy/CRP and H&Y, H&Y and MMSE/NMSS, Hcy/CRP and
L-dopa dosage, and Hcy/CRP and disease duration. The
variables tested included age, disease duration, H&Y, MMSE,
NMSS, UPDRS III, Hcy and CRP. SPSS 13.0 software (Chicago,
IL, USA) was used for the statistical analyses. P values of less than
0.05 were regarded as statistically significant.
Results
Patient characteristics
In total, 88 PD subjects, including 43 PD patients [25 males (58.1%)
and 18 females (41.9%)] and 45 VP patients [23 males (51.1%) and 22
females (49.9%)], were enrolled in this cross-sectional study. The
mean ages of the PD and VP patients were 58613.74 years (range, 43
to 83) and 67611.6 years (range, 45 to 83), respectively. The mean
durations of PD and VP symptoms were 6.263.7 years (range, 0.08 to
26) and 5.864.2 years (range, 0.06 to 14), respectively. The H&Y
stages ranged from 1 to 4 for patients with PD and VP. With respect to
the levodopa (L-dopa) therapy, the average dosages were 392.3 mg
and 383.3 mg daily for PD and VP, respectively. Details of the
demographics of all 88 patients are listed in Table 1.
The mean age for patients with VP was higher than that in the
PD patients (67.03 vs. 58.88, P=0.006), and the MMSE for
patients with VP was lower than that in PD patients (22.08 vs.
25.32, P=0.007, Table 2). No significant difference in the Hcy,
CRP, BMI, UPDRS III, or nine dimensions of NMSS was found
between the PD and VP patients.
When the PD and VP subjects were divided into two groups
(age#60,age.60), the levels of CRP in the PD patients above 60
years old were significantly higher than those in the PD patients
younger than 60 years old (3.04 vs.1.47, P=0.005, Table 3), and
the levels of Hcy in VP patients above 67 years old were
significantly higher than those in VP patients younger than 67
years old (16.79 vs. 12.78, P=0.009, Table 3)
Correlations between UPDRS III and Hcy/CRP, UPDRS III
and MMSE, NMSS domains and Hcy/CRP, Hcy/CRP and
H&Y, Hcy/CRP and L-dopa dosage, Hcy/CRP and disease
duration, and Hcy/CRP and MMSE
There was a significant correlation between UPDRS III and
CRP (rS=0.656, P=0.011, Table 4) as well as between UPDRS
III and NMSS (rS=0.550, P=0.042, Table 4) in patients with PD.
Table 2. Comparison of age, BMI, Hcy, CRP, UPDRS (III),






Age 58.88613.7 67.03611.58 2.809 0.006*
Hcy 14.0860.77 15.1260.90 0.087 0.39
CRP 2.0660.28 2.5960.39 1.136 0.26
BMI 22.8062.12 21.6862.37 1.247 0.224
MMSE 25.3262.18 22.0862.93 2.955 0.007*
UPDRS(III) 17.8965.65 19.23610.60 0.389 0.701
NMSS
(total)
131.1469.24 135.57648.76 0.671 0.508
Cardiovascular 2.2162.39 2.6462.31 20.483 0.633
Sleep/Fatigue 28.1469.69 26.57610.11 0.420 0.678
Mood 27.14613.31 26.43612.38 0.144 0.886
Perceptual
problem
7.3667.06 9.7167.67 20.846 0.405
Attention/
memory
13.2966.60 13.0767.56 0.081 0.936
Gastrointestina 11.5769.75 12.5768.78 20.285 0.778
Urinary 13.2167.91 12.3668.10 0.283 0.779
Sexual function 13.6466.29 15.8866.8 20.894 0.380
Miscellaneous 15.64610.72 16.3669.79 20.192 0.849
* P,0.01.
Abbreviations: SD, Standard deviation; BMI, Body Mass Index; MMSE, mini-
mental state examination; UPDRS III, the unified Parkinson’s disease rating scale
part III; and NMSS, non-motor symptoms scale for Parkinson’s disease (range of
possible scores from 0 to 360).
doi:10.1371/journal.pone.0019333.t002
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P=0.002, Table 4), CRP (rS=0.852, P=0.000, Table 4), and
NMSS (rS=0.602, P=0.023, Table 4) in patients with PD. In the
VP patients, the UPDRS III and H&Y were not significantly
associated with NMSS, Hcy, CRP, or MMSE. Significant
correlations were observed between Hcy and NMSS in PD and
VP patients (rS=0.795/842, P=0.001/0.000/,0.001, respective-
ly, Table 5). Similarly, the CRP and NMSS also strongly correlated
with NMSS (rS=0.781/699, P=0.001/0.005/,0.001, respective-
ly, Table 5). Specifically, when evaluating the correlation between
Hcy and the different NMSS dimensions in PD and VP, significant
correlations, from low to high, were observed in miscellaneous
(P=0.042 for VP), urinary (P=0.009 for PD), mood (P=0.009 for
VP), urinary (P=0.005 for VP), mood (P=0.001 for PD), and
sleep/fatigue (P,0.000 for VP). Similarly, when evaluating the
correlation between CRP and the different NMSS dimensions in
PD and VP, significant correlations, from low to high, were
observed in mood (P=0.029 for VP), sleep/fatigue (P=0.013 for
VP), urinary (P=0.01 for PD), miscellaneous (P=0.007 for VP),
gastrointestinal (P=0.004 for PD), urinary (P,0.002 for VP), and
mood (P=0.001 for PD). For the remaining four dimensions, no
significantcorrelationswerefound(Table5).Inaddition, Hcy/CRP
were significantly associated with L-dopa dosage for both PD and
VP patients (P,0.001, Table 6), and Hcy/CRP were correlated
with H&Y (P,0.01, Table 6) in PD patients. No significant
correlations were found between Hcy/CRP and MMSE and Hcy/
CRP and disease duration in patients with PD.
Discussion
PD is the second most common neurodegenerative disorder
following AD and is characterized by a disturbance of the central
dopaminergic system; the concept of VP was first mentioned by
Critchley in 1929 [29]. Over the past few years, correlations
between VP and PD patients have received significant attention in
the diagnosis, therapy, and evaluation of these two diseases
[17,26,27,28]. The primary goals of this study were to compare
Chinese patients with PD and VP by systematically collecting
information about demographics, such as age and disease
duration, motor and non-motor dysfunctions, and the serum
levels of CRP and Hcy. To the best of our knowledge, this report is
the first to evaluate the association between motor/non-motor
effects and CRP/Hcy in Chinese patients with PD and VP using
unified and integrated scales (NMSS, H&Y, and MMSE).
In this study, the VP group presented many characteristics, such
as resting tremor, postural instability, and rigidity, that are similar
to those described in the original VP report by Critchley [29]. We
found that NMS (including cardiovascular, sleep, and mood
disorders) were very common in Chinese patients with PD and
VP, with a prevalence of NMS in the group being 100%, and the
NMSS for PD (mean=131.14, Table 1) was consistent with a
previous report [15]. However, we did not find a significant
difference in NMS between PD and VP, which suggests that NMS
equally influenced PD and VP in Chinese subjects. Interestingly,
as shown in Tables 1 and 2, our patients with VP were significantly
older than those patients with PD, and a shorter duration of
symptoms in the VP group was also observed. This finding has also
been documented in some other VP studies [26,27], and it implies
that Chinese VP subjects developed symptoms later in life but
experienced deterioration faster than the PD patients. Addition-
ally, a later age at onset of VP would favor a vascular cause.
Interestingly, a significant reduction of the MMSE was observed in
VP patients when compared to the PD group (mean=25.32 for
PD, mean=22.08 for VP, P=0.007, Table 2). This result
demonstrated that compared to PD subjects, Chinese VP patients
had already undergone a greater decline in cognitive function by
the time they visited a neurologist. This result is in agreement with
Zijlmans’ point [17] and implies that our VP patients may have
more subcortical lesions than patients with PD and that this
subcortical vascular cause may have led to the declined cognition.
Recent studies have shown that inflammatory responses are
observed in the nigrostriatal regions of dopaminergic degenera-
tion, and some protective strategies against inflammatory devel-
opment occur when anti-inflammatory medications are taken.
Among those inflammatory mediators, Hcy and CRP have
received substantial attention for the past 15 years as having an
important role in and potentially as risk factors for PD. An
Table 3. Comparison of Hcy and CRP among patients with
PD and VP.
Variable PD VP
Age#60 Age.60 P Age#67 Age.67 P
Hcy 14.5065.82 13.6563.18 0.604 12.7863.88 16.7965.55 0.009*
CRP 1.4760.96 3.0462.21 0.005* 3.3160.91 3.2760.82 0.97
* P,0.01
doi:10.1371/journal.pone.0019333.t003
Table 4. Spearman’s rank correlation coefficient (rs) and P values between UPDRS III and clinical variables, and between H&Y and
clinical variables.
Variable UPDRS(III) (PD) H&Y (PD) UPDRS(III) (VP) H&Y (VP)
r P r P r P r P
Hcy 0.463 0.096 0.759 0.002 0.216 0.459 0.637 0.014*
CRP 0.656 0.011* 0.852 0.000** 0.013 0.964 0.453 0.104
BMI 20.053 0.858 0.191 0.514 0.132 0.654 0.431 0.124
MMSE 20.308 0.284 20.322 0.262 20.203 0.486 20.522 0.056
NMSS (total) 0.550 0.042* 0.602 0.023* 0.318 0.268 0.735 0.040*
* P,0.05,
** P,0.001.
Abbreviations: rs, Spearman’s rank correlation coefficient; H&Y, the modified Hoehn and Yahr staging scale; UPDRS III, the unified Parkinson’s disease rating scale part III;
MMSE, mini-mental state examination; NMSS, non-motor symptoms scale for Parkinson’s disease.
doi:10.1371/journal.pone.0019333.t004
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cognition and dementia in the general population [30], and it has
been well documented to be associated with mild cognitive
impairment (MCI), Alzheimer’s disease (AD), PD, and vascular
dementia [7,11,31]. Similarly, increased plasma CRP is correlated
to myocardial infarction, PD, and ischemic stroke [6,32].
However, limited studies have investigated the association of the
combination of Hcy and CRP in PD and VP subjects. To clarify,
to determine if Hcy and CRP contribute to the motor dysfunction
and cognitive decline in VP and PD patients, we examined the
plasma Hcy/CRP and compared their levels in PD and VP
patients. Our data did not show a significant difference in Hcy and
CRP between the PD and VP groups (Table 2). This result
demonstrates that the inflammatory mediators Hcy and CRP
might contribute equally to the progression of these two diseases.
Interestingly, when we separated the subjects into two groups
according to age (,60 and .60), we noticed that the CRP levels
in PD subjects above 60 years old were much higher than those
patients under 60, whereas the Hcy levels in VP subjects above 60
were less than those under 60 (Table 3). Two reasons probably led
to the discrepancy in the CRP and Hcy levels in patients with PD.
First, as a neurodegenerative disease, PD exacerbates with age,
and the inflammatory process aggravates the progression in PD
patients above 60 when compared to patients under 60. This
exacerbated inflammatory response in PD patients above 60 can
be reflected in the obviously elevated levels of CRP, a biomarker of
systemic inflammation. Second, Hcy, though recognized as an
indicator of neurotoxic mediator, is profoundly affected by several
factors, such as some B-vitamin (folate, and B12, and B6)
deficiencies, genetic polymorphisms of MTHFR and CßS, and
L-dopa intake [11,33]. These influences may have lead to the
unchanged level of Hcy between PD patients above and under 60
in this study. We did not observe a significantly changed level of
CRP, but we did observe a significant upregulation of Hcy in VP
patients above 67 when compared with those under 67. The
precise reasons remain unclear, but it may reflect a different
pathogenesis for PD and VP, the latter of which mainly results
from subcortical vascular causes; additionally, Hcy is obviously
Table 5. Spearman’s rank correlation coefficient (rs) and P values between NMSS domains and Hcy, and between NMSS domains
and CRP.
Variable Hcy (PD) CRP (PD) Hcy (VP) CRP (VP)
rp rp rP rP
NMSS (total) 0.795 0.001** 0.781 0.001** 0.842 0.000*** 0.699 0.005**
Cardiovascular 0.503 0.067 0.474 0.087 0.284 0.326 0.178 0.543
Sleep/Fatigue 0.478 0.084 0.477 0.084 0.854 0.000*** 0.642 0.013*
Mood 0.767 0.001** 0.801 0.001** 0.666 0.009** 0.581 0.029*
Perceptual problem 0.528 0.052 0.649 0.012* 0.496 0.071 0.257 0.375
Attention/memory 0.232 0.424 0.224 0.440 0.331 0.248 0.134 0.647
Gastrointestina 0.485 0.078 0.722 0.004** 0.540 0.046* 0.349 0.221
Urinar 0.668 0.009** 0.660 0.010* 0.702 0.005** 0.740 0.002**
Sexual function 0.299 0.299 0.162 0.580 0.471 0.089 0.396 0.161




Abbreviations: rs, Spearman’s rank correlation coefficient; NMSS, non-motor symptoms scale.
doi:10.1371/journal.pone.0019333.t005
Table 6. Spearman’s rank correlation coefficient (rs) and P values between Hcy and clinical variables, and between CRP and clinical
variables.
Variable Hcy (PD) CRP (PD) Hcy (VP) CRP (VP)
rp rp r P r P
Hcy 1 0.912 0.000*** 1 0.686 0.007**
CRP 0.912 0.000*** 1 0.686 0.007** 1
Daily L-dopa dosage 0.814 0.000*** 0.693 0.006** 0.854 0.000*** 0.698 0.005**
H&Y 0.759 0.002** 0.852 0.000*** 0.637 0.014* 0.453 0.104
Disease duration 0.460 0.098 0.447 0.109 0.531 0.051 0.616 0.019*




Abbreviations: rs, Spearman’s rank correlation coefficient; H&Y, the modified Hoehn and Yahr staging scale; MMSE, mini-mental state examination.
doi:10.1371/journal.pone.0019333.t006
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suggest that the chronic inflammatory response may be worse in
older PD patients and that an anti-inflammatory strategy would be
useful in the management of PD.
Spearman’s rank correlation coefficients were determined to
explore the association of UPDRS III with the Hcy, CRP, H&Y,
MMSE and NMSS in PD and VP. Similar to our previous report
[15], highly significant correlations were observed between motor
dysfunctions and NMS burden in patients with PD (rS= 0.550,
P=0.042, Table 4). This result suggests that both disease severity
and motor dysfunctions may influence NMS in PD and that NMS
may have multiple effects on the motor complications in PD.
Interestingly, no correlations were found between the UPDRS III
and Hcy in PD (rS= 0.463, P=0.096, Table 4) and VP (rS=
0.216, P=0.459, Table 4) or between the UPDRS III and CRP in
VP (rS= 0.013, P=0.964, Table 4). However, similar to the result
in Table 3, the inflammatory mediator CRP was closely correlated
to UPDRS III in the PD group (rS=0.656, P=0.011, Table 4),
further demonstrating that the inflammatory response in PD
patients may contribute to motor dysfunction [36].
To further correlate the association of the individual domains of
NMS with Hcy, CRP, and H&Y, we identified that some
dimensions of NMS in PD and VP significantly correlated with
the Hcy and CRP (Table 5) using the Spearman’s rank correlation
coefficient analysis. Clinical associations of elevated CRP levels in
PD and VP patients have not, to our knowledge, previously been
described. Although our results (Table 5) indicate the percent
variation, they only explain the rS separately and did not take into
account the contributions of the other domains. Significant
correlations (Table 4) were also observed between the H&Y and
NMSS in both PD and VP. This result is consistent with our
previous study [15] and implies that the disease severity for both
PD and VP influences non-motor dysfunctions. In addition, these
data show that Hcy and CRP are highly correlated with NMS in
both PD and VP patients (Table 5). Specifically, Hcy and CRP
have robust association with mood and urinary domains, further
demonstrating that these two dysfunctions would be important
targets for evaluation by plasma levels of Hcy and CRP.
Consistent with our notions, one study by O’Suilleabhain also
reported that a high level of Hcy was correlated to mood
deterioration [37].
In our study, the associations between Hcy/CRP and L-dopa,
H&Y, the disease duration, and the MMSE in PD and VP were
investigated. Profound associations were observed between Hcy
and L-dopa dosage as well as between Hcy and H&Y in PD and
VP patients (Table 6). This result is consistent with previous
reports [11,37,38,39], and it may imply that levodopa drains
methylation reserves: methylation of levodopa and dopamine
converts the methyl donor methionine into Hcy [37]. The L-dopa
related plasma Hcy may contribute to the progression of PD/VP
and the development of motor dysfunction, which is reflected in
the observed significant correlation between the H&Y score and
Hcy (Table 6). Similarly, significant associations between CRP and
L-dopa dosage as well as between CRP and H&Y in PD were
obtained. This result suggests that as an inflammatory biomarker,
CRP might be used to predict the severity or outcome in PD
patients. Interestingly, no significant correlation was obtained
between Hcy/CRP and the MMSE in either PD or VP, implying
that Hcy and CRP plasma levels did not predict the cognitive
status of PD and VP patients. This result is consistent with Barone
and Rodriguez-Oroz’s studies, which showed a similar degree of
cognitive impairment in PD patients with low and high Hcy levels
[7,40].
Several limitations of this study should be noted: (1) only a small
number of PD patients (88 patients) were recruited, and the
disease durations were relatively short (3.7 years for PD and 4.2
years for VP); (2) the UPDRS III scale had a low mean score
(mean =17.89 for PD, 19.23 for VP); (3) mainly PD patients in the
early stages of disease were enrolled, as indicated by the low
median stage of the H&Y scale and the relatively high MMSE
score (25.32 for PD, 22.08 for VP); (4) genetic factors such as the
MTHFR genotype and folate administration were not considered
in this study; and (5) to validate and complete the questionnaire,
we only chose PD and VP subjects with sufficient cognitive ability,
significantly narrowing the population in this study. The
population chosen according to the above (1)-(4) in this study
may produce a bias for Hcy and CRP levels in PD and VP
patients. Therefore, larger studies need to be done, expanding this
work to a broader population. In addition, different stages of PD
patients in both UPDRS III and H&Y scores should be included
to compensate for current shortcomings.
In conclusion, our findings support the hypothesis that as
exquisitely sensitive systemic mediators of inflammation, Hcy and
CRP play important roles in the pathogenesis of PD. To our best
knowledge, this report is the first to combine the plasma levels of
Hcy and CRP to assess the progression of PD and VP. The
combination of Hcy and CRP, especially CRP, may predict the
outcomes of non-motor dysfunctions in PD and VP. A causal link
in either direction is feasible; a systemic Hcy and CRP change may
predispose a person to PD or VP or otherwise impair
dopaminergic neuronal function. Alternatively, worse parkinson-
ism may predispose a person to the alteration of Hcy and CRP due
to some medication factors, such as L-dopa treatment. Our
findings, if confirmed, indicate that disease burden in patients with
PD and VP, such as poor motor performance, disease severity, and
urinary dysfunction, is associated with plasma Hcy and CRP
levels. Whether or not anti-inflammatory medication could be
used in the management of PD and VP will produce interesting
work in the future.
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